Promising prostate cancer combo trial pulled before starting
NCT ID NCT06765954
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed for men with high-risk prostate cancer who cannot have surgery. It planned to combine three experimental drugs (N-803, ETBX-071, and M-CENK) with radiation to boost the immune system's attack on cancer. Researchers aimed to see if the treatment could eliminate cancer cells and lower PSA levels. However, the trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Man's best friend as cancer detector: can dogs sniff out prostate cancer?
- Can a single radiation type spare prostate cancer patients from extra side effects?
- New scan could reveal hidden cancer in High-Risk prostate patients
- New scan could revolutionize prostate cancer monitoring
- New immunotherapy combo targets High-Risk prostate cancer before and after surgery
- New cocktail aims to wipe out prostate cancer before surgery